# LifeMD, Inc.: Form 10-Q for the period ended Mar 31, 2017

- Company: [LifeMD, Inc.](/companies/lfmd.md) (CIK 948320)
- Form: 10-Q
- Filed: 2017-07-07
- Accepted by EDGAR: Jul 7, 2017, 16:53 ET
- Period: 2017-03-31
- Accession: 0001213900-17-007275
- Inline XBRL: yes
- Main document: https://www.sec.gov/Archives/edgar/data/948320/000121390017007275/f10q0317_immudyneinc.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/948320/000121390017007275/

## Figures reported in this filing

Standardized XBRL line items for the period ended 2017-03-31.

| Line item | Period | Value | XBRL concept |
| --- | --- | ---: | --- |
| Revenue | 3 months, 2017-01-01 to 2017-03-31 | $424.5k | us-gaap:Revenues |
| Cost of revenue | 3 months, 2017-01-01 to 2017-03-31 | $203.4k | us-gaap:CostOfRevenue |
| Gross profit | 3 months, 2017-01-01 to 2017-03-31 | $221.1k | us-gaap:GrossProfit |
| Operating income | 3 months, 2017-01-01 to 2017-03-31 | −$375.0k | us-gaap:OperatingIncomeLoss |
| Interest expense | 3 months, 2017-01-01 to 2017-03-31 | $649.4k | us-gaap:InterestExpense |
| Net income | 3 months, 2017-01-01 to 2017-03-31 | −$1.0m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months, 2017-01-01 to 2017-03-31 | −$0.03 | us-gaap:EarningsPerShareBasicAndDiluted |
| Diluted shares (weighted) | 3 months, 2017-01-01 to 2017-03-31 | 37,581,987 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 3 months, 2017-01-01 to 2017-03-31 | −$473.3k | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Cash and equivalents | at 2017-03-31 | $381.1k | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | at 2017-03-31 | $1.1m | us-gaap:AssetsCurrent |
| Total assets | at 2017-03-31 | $1.1m | us-gaap:Assets |
| Current liabilities | at 2017-03-31 | $2.4m | us-gaap:LiabilitiesCurrent |
| Shareholders' equity | at 2017-03-31 | −$1.1m | us-gaap:StockholdersEquity |

## Management's discussion and analysis

As filed, 16,544 characters.

### Overview

We are a health and wellness company that develops, manufactures, and markets innovative consumer products. We manufacture and market a proprietary and patent protected Yeast Beta Glucan that has been shown in clinical studies to support and regulate the human immune system. It has broad applications in skincare and as an immune support supplement. Our majority owned subsidiary is our digital marketing arm and is currently focused on marketing patented products for thicker and fuller hair and a skincare line containing our proprietary Yeast Beta Glucan ingredient.

We have performance based contracts with our sales and marketing executives, which allows us to continue to maintain a relatively low overhead. Our priority is to pursue opportunities to market our products and increase sales. We expect that a significant component of our selling, general and administration expenses going forward will consist of equipment leasing costs relating to improving our operating efficiencies, as well as conducting new studies which could open new markets. These aforementioned costs, along with the additional costs resulting from our operations as a public reporting company, could adversely impact our future results of operations. Additional significant factors that we believe will affect our operating results going forward are: (i) protection of our intellectual property rights; (ii) imposition of more stringent government regulations of our products; and (iii) marketing expenses.

In the 2016 fiscal year, we utilized third party entities to provide and increase credit card processing capacity and optimize corresponding rates and fees through one or more merchant bank accounts held by such entities. A majority of these entities providing these services are consolidated as VIEs which received a one (1%) percent fee eliminated in consolidation of the net revenues processed and collected by such contractors from sales initiated by the Company. The remaining entities provided such services as independent contractors, the majority of which were considered related parties and no fee was paid. Upon receipt of funds by such contractors from their respective merchant banks, the Company required the prompt transfer of funds to Company controlled accounts. The Company reimbursed and/or advanced funds to such contractors for any deficit or charge related to returns, chargeback and other fees charged by such merchant bank. Some of the entities contracted to provide these services have been determined to be variable interest entities and consolidated in the Company’s financial statements.

We historically have expended a significant amount of our funds on obtaining and protecting our patents, trade secrets and proprietary products. We rely on the patent and trademark protection laws in the U.S. to protect our intellectual property and maintain our competitive position in the marketplace. For several years, we were involved in complex litigation regarding patents and licenses critical to our products. In 2010, we prevailed on all major legal matters and reached favorable settlements. If additional litigation becomes necessary to protect our intellectual property rights, such litigation may be costly, divert our management’s attention away from our core business and have a negative impact on our operations. Furthermore, there is no guarantee that litigation would result in an outcome favorable to us. In addition, yeast beta glucans are designated as GRAS under current FDA regulations. Future government regulations may prevent or delay the introduction or require the reformulation of our products. Some agencies, such as the FDA, could require us to remove a particular product from the market, delay or prevent the import of raw materials for the manufacture of our products or otherwise disrupt the marketing of our products. Any such government actions could result in additional costs to us, reduced growth prospects, lost sales from products that we are required to remove from the market and potential product liability litigation.

We have historically operated with limited capital and have funded operations in the past through the sales of our products and loans and advances from Mark McLaughlin, our President, and other directors, as well as from debt and equity financings. We plan on our operating business (in conjunction with proceeds from debt and equity financings completed in 2016 and early 2017) being able to fund our operations through 2017. However, if necessary, we may raise additional capital through a private placement of common stock, obtaining debt financing or from advances from our President and/or directors; however, no assurances can be made that we will be successful in our endeavors to raise additional capital. For additional information regarding these and other risks please see “Risk Factors” contained in our annual report for the fiscal year ended December 31, 2016.

### Results of Operations

### Three Months Ended March 31, 2017, Compared to the Three Months Ended March 31, 2016

The following table sets forth the results of our operations for the periods indicated as a percentage of net sales:

|  | 2017 $% of Sales |  | 2016 $% of Sales |  |
| --- | ---: | ---: | ---: | ---: |
| Net Sales | 424,462 |  | 1,641,028 |  |
| Cost of sales | 203,356 | 48% | 1,337,942 | 82% |
| Gross profit | 221,106 | 52% | 303,086 | 18% |
| Operating expenses | (596,092) | (140)% | (408,182) | (25)% |
| Operating (Loss) | (374,986) | (88)% | (105,096) | (6)% |
| Change in fair value of derivative liability | (48,192) | (11)% | - | -% |
| Interest (expense) | (649,357) | (153)% | (3,063) | -% |
| Net (loss) | (1,072,535) | (253)% | (108,159) | (7)% |
| Net (loss) attributable to noncontrolling interests | (27,730) | (7)% | (46,110) | (3)% |
| Net (loss) attributable to Immudyne, Inc. | (1,044,805) | (246)% | (62,049) | (4)% |

Overall sales for the three months ended March 31, 2017 were $0.42 million, a decrease of 74% from $1.64 million for the same period in 2016. Our decrease in sales was due to the fact that we invested considerable time and Company resources into the preparation for the launch of our in-licensed patented hair loss shampoo, conditioner, and leave in foam during the first quarter of 2017, which we believe, based on initial sales numbers, will be a meaningful contributor to our revenues during the remainder of the 2017 fiscal year. In addition, during the quarter, we shifted to an internal marketing strategy which we believe will position the Company for long-term success. However, this shift impacted our overall sales numbers for our finished products segment which decreased to $0.17 million for the quarter compared to $1.38 million for the three months ended March 31, 2016. Sales in our additives segment remained relatively consistent between periods at $0.26 million for the three months ended March 31, 2017 compared to $0.27 million for the same period in 2016, which is in-line with our expectations and the historical performance of this segment.

Cost of sales consists primarily of material costs, labor costs, marketing costs and related overhead directly attributable to the production of our products. Total cost of sales decreased 85% to $0.20 million in the first quarter of 2017 compared to $1.34 million for the same period in 2016. The decrease in our cost of sales was due to our decreased revenues and as a result of the increased advertising and marketing expenses we incurred in the first quarter of 2016 to generate our significant increase in sales from our finished cosmetic products segment during that period.

Gross profit decreased 27% to $0.22 million in the first quarter of 2017 compared to $0.30 million for the same period in 2016. The decrease in our gross profit was a result of our decrease in sales, which was partially offset by the fact that we did not incur the same level of advertising and marketing expenses as we did in the first quarter of 2016.

Gross profit as a percentage of sales increased to 52% in the first quarter of 2017 from 18% for the same period in 2016. Our increase in gross profit as a percentage of sales for the quarter was as a result of the fact that our sales for the quarter were more heavily weighted towards our additives segment which generally has higher margins.

Operating expenses consisted of general and administrative expense, compensation and related expense and professional fees. Overall operating expenses increased 46% to $0.60 million in the first quarter of 2017 from $0.41 million for the same period in 2016. The relative consistency in our operating expenses between the periods despite our decrease in sales was primarily attributable to our continued compensation commitments, including with respect to our joint venture. General and administration expense increased 30% to $0.13 million in the first quarter of 2017 from $0.10 million for the same period in 2016. Compensation and related expense increased 50% to $0.36 million in the first quarter of 2017 from $0.24 million for the same period in 2016. Professional fees increased 44% to $0.10 million in the first quarter of 2017 from approximately $0.07 million for the same period in 2016, due to increased legal and accounting fees incurred with respect to our operations in Puerto Rico.

Net loss attributable to the Company in the first quarter of 2017 was approximately $1.04 million compared to net loss of $0.06 million for the same period in 2016. We consolidated the operations of our joint venture, Immudyne PR and reflected a non-controlling interest for 21.8333% of these operations. Net loss attributable to the Company as a percentage of sales was 246% in the first quarter of 2017 compared to net loss as a percentage of sales of 4% for the same period in 2016. Our net loss during the period was attributable to the aforementioned decrease in our sales as we shifted company resources in efforts to launch our in-licensed patented hair loss shampoo, conditioner, and leave in foam, and to internal marketing strategies. It was also partially attributable to a $0.55 non-cash charge related to the settlement of a notes payable in connection with the conversion of such note to shares of common stock and warrants. We believe these developments will positively impact the Company’s business during the 2017 fiscal year.

### Liquidity and Capital Resources

Our principal demands for liquidity are to increase sales, purchase inventory and for sales distribution and general corporate purposes. We incurred negative operating cash flows in the 2016 and 2015 fiscal years. As a result, we have substantial doubt about our ability to continue as a going concern. Late in the 2016 fiscal year and early in 2017, the Company issued several 11% subordinated promissory notes to accredited investors for total borrowings of $200,000. Additionally, the Company borrowed $200,000 at 11% from an investor and borrowed $100,000 from an officer of the Company. Each of these borrowings have since been satisfied in full with a combination of repayment in cash and conversion of certain amounts outstanding to equity of the Company. The Company also has access to a working capital line in the amount of $25,000 with a term of 60 days and interest at a flat fee of $250. As of March 31, 2017, there were no available borrowings under the working capital line. Additionally, in the first quarter of 2017, the Company issued and sold 2,817,156 shares and 1,408,578 warrants to accredited investors in an offering pursuant to Regulation D and received proceeds in the amount of $647,944. We plan on our operating business (in conjunction with proceeds from debt and equity financings completed in 2016 and early 2017) being able to fund operations through 2017. However, if necessary, we may raise additional capital through a private placement of common stock, obtaining debt financing or from advances from our President and/or directors; however, no assurances can be made that we will be successful in our endeavors to raise additional capital.

There can be no assurance that required future financing can be successfully completed on a timely basis, or on terms acceptable to us. Any future issuance of equity securities could cause dilution to our shareholders. Any incurrence of indebtedness would increase our debt service obligations and would cause us to be subject to restrictive operating and financial covenants.

We had negative net working capital of approximately $(1,323,408) at March 31, 2017, resulting in a decrease from negative net working capital of approximately $(361,725) at December 31, 2016. The ratio of current assets to current liabilities was .45 to 1 at March 31, 2017.

The following is a summary of cash provided by or used in each of the indicated types of activities during the three months ended March 31, 2017 and 2016:

| Cash provided by (used in): | 2017 | 2016 |
| --- | ---: | ---: |
| Operating activities | $(473,256) | $(122,155) |
| Financing activities | 671,751 | 92,793 |

Net cash flow used by operating activities was $0.47 million for the three months ended March 31, 2017, compared to net cash flow used in operating activities of $0.12 million for the same period in 2016. The increase in the amount of cash used by our operating activities was due primarily to our overall net loss for the quarter.

Net cash flows provided by financing activities was $0.67 million for the three months ended March 31, 2017, compared to net cash flows provided by financing activities of $0.09 million for the same period in 2016. Our increase in net cash flows provided by financing activities was primarily a result of the sale of our common stock and warrants in the first quarter of 2017 for aggregate proceeds of $0.65 million.

### Indebtedness

From time to time, our directors, officers and other related individuals have made short-term advances to us for our operating needs. Late in the 2016 fiscal year and early in 2017, the Company issued several 11% subordinated promissory notes to accredited investors for total borrowings of $200,000, borrowed $200,000 at 11% from an investor and borrowed $100,000 from an officer of the Company. Each of these borrowings have since been satisfied in full with a combination of repayment in cash and conversion of certain amounts outstanding to equity of the Company. We also have access to a $25,000 working capital line. As of March 31, 2017, there were no available borrowings under the working capital line.

We are subject to a royalty agreement pursuant to which we are required to pay a monthly royalty of 8% on all sales of certain skin care products up to $227,175. During the year ended December 31, 2015 our sales reached the maximum amount under which we are required to pay a royalty under this agreement, accordingly no royalty expense was incurred for the three months periods ending March 31, 2017 and 2016. During 2015, our President, who has a 60% interest in the royalties, converted all royalties payable (in the amount of $84,868) to 499,225 shares of the company’s stock valued at $0.17 cents a share.

### Off-Balance Sheet Arrangements

There are no off-balance sheet arrangements between us and any other entity that have, or are reasonably likely to have, a current or future effect on our financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources that is material to shareholders.

We have not entered into any financial guarantees or other commitments to guarantee the payment obligations of any third parties. We have not entered into any derivative contracts that are indexed to our shares and classified as stockholders’ equity or that are not reflected in our consolidated financial statements. Furthermore, we do not have any retained or contingent interest in assets transferred to an unconsolidated entity that serves as credit, liquidity or market risk support to such entity. We do not have any variable interest in any unconsolidated entity that provides financing, liquidity, market risk or credit support to us or engages in leasing, hedging or research and development services with us.

### Critical Accounting Policies

Our significant accounting policies are described more fully in Note 2 to our financial statements, which we believe are the most critical to aid you in fully understanding and evaluating this management discussion and analysis.

## Controls and procedures

As filed, 2,732 characters.

### Disclosure Controls and Procedures

We carried out an evaluation, under the supervision and with the participation of our Principal Executive Officer (“PEO”), who is also our Principal Financial Officer (“PFO”), of the design and effectiveness of our “disclosure controls and procedures” (as defined under Rules 13a-15(e) and 15d-15(e) of the Securities Exchange Act of 1934) as of the end of the period covered by this report. Based on this evaluation, our PEO/PFO concluded that as of the end of the period covered by this report, these disclosure controls and procedures were not effective. The conclusion that our disclosure controls and procedures were not effective was due to the presence of the following material weaknesses in disclosure controls and procedures which are indicative of many small companies with small staff: (i) inadequate segregation of duties and effective risk assessment as the Company had only one officer; (ii) insufficient written policies and procedures for accounting and financial reporting with respect to the requirements and application of both US GAAP and SEC Guidelines; and (iii) inadequate security and restricted access to computer systems including insufficient disaster recovery plans; and (iv) no written whistleblower policy. If and when sufficient funds are available, our PEO/PFO plans to implement appropriate disclosure controls and procedures to remediate these material weaknesses, including (i) appointing additional qualified personnel to address inadequate segregation of duties and ineffective risk management; (ii) adopt sufficient written policies and procedures for accounting and financial reporting and a whistle blower policy; and (iii) implement sufficient security and restricted access measures regarding our computer systems and implement a disaster recovery plan.

### Changes in Internal Control over Financial Reporting

There were no changes in our internal control over financial reporting (as such term is defined in Rules 13a-15(f) and 15d-15(f) of the Exchange Act) that occurred during the quarter ended March 31, 2017, that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting. In designing and evaluating the disclosure controls and procedures, management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives. In addition, the design of disclosure controls and procedures must reflect the fact that there are resource constraints and that management is required to apply its judgment in evaluating the benefits of possible controls and procedures relative to their costs.

## Risk factors

As filed, 145 characters.

You should consider carefully the factors discussed in the “Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2016.

Filed Jul 7, 2017.
Source: SEC EDGAR, the filing index for accession 0001213900-17-007275. Last ingested by Listed: Nov 13, 2026, 16:33 ET. No prices; not investment advice.
